- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00336596
Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion
April 25, 2007 updated by: University of Zurich
Transcranial Ultrasound Enhanced Thrombolysis (TRUST)
The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz TCCS in stroke patients treated with intravenous tissue plasminogen activator (t-PA) within 3 hours after symptom onset.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Thrombolysis with intravenous(iv) tissue plasminogen activator (t-PA) is the only effective and approved therapy for acute ischemic stroke.
The most frequent cause of ischemic stroke is thrombosis of the middle cerebral artery (MCA).
Preliminary in vitro, animal and human studies suggest that ultrasound accelerates thrombolysis induced by t-PA, and recanalization of acute MCA occlusion due to thrombolysis is an independent predictor of good clinical outcome.
Thus, insonation of an occluded MCA through the temporal bone in stroke patients who are treated with iv t-PA might enhance recanalization and improve clinical outcome.
The present prospective, randomized, controlled multicenter pilot study will investigate the safety and efficacy of continuous 1-hour insonation of the occluded MCA with 2 MHz transcranial color duplex sonography in patients with ischemic stroke treated with iv t-PA within 3 hours after symptom onset.
It is planned to randomize 400 patients in 6 Swiss centers during an enrolment period of 33 months with an individual follow up of 3 months.
The study endpoints include safety and efficacy assessments.
The primary safety endpoint is to determine the rate of symptomatic intracranial hemorrhage (ICH) in both treatment groups.
The primary efficacy endpoint is to determine whether a good functional outcome (modified Rankin scale, mRs, score of 0-2) differs between both treatment groups.
Secondary endpoints include (1) asymptomatic ICH occuring during or within the first 24-48 hours after t-PA infusion, (2) early clinical recovery by 10 or more National Institute of Health Stroke Scale (NIHSS) points or dramatic recovery (total NIHSS score of 3 or less) at 24-48 hours after t-PA infusion, (3) mean mRS score at 90 days after t-PA infusion, (4) death occuring during the study period, and (5) recanalization at 24-48 hours after t-PA infusion.
Study Type
Interventional
Enrollment
400
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aarau, Switzerland
- Recruiting
- Kantonsspital Aarau, Department of Neurology
-
Contact:
- Hansjörg Hungerbühler, MD
- Phone Number: +41 62 838 66 75
- Email: hansjoerg.hungerbuehler@ksa.ch
-
Principal Investigator:
- Hansjörg Hungerbühler, MD
-
Basel, Switzerland
- Recruiting
- University Hospital of Basel, Department of Neurology
-
Contact:
- Stefan Engelter, MD
- Phone Number: +41 61 265 25 25
- Email: sengelter@uhbs.ch
-
Principal Investigator:
- Philippe Lyrer, MD
-
Principal Investigator:
- Stefan Engelter, MD
-
Bern, Switzerland
- Recruiting
- University hospital of Bern, Department of Neurology
-
Contact:
- Marcel Arnold, MD
- Phone Number: +41 31 632 33 32
- Email: marcel.arnold@insel.ch
-
Principal Investigator:
- H.-P. Mattle, MD
-
Principal Investigator:
- Marcel Arnold, MD
-
Geneva, Switzerland
- Recruiting
- University Hospital of Geneva, Department of Neurology
-
Contact:
- Roman Sztajzel, MD
- Phone Number: +41 22 372 83 10
- Email: Roman.Sztajzel@hcuge.ch
-
Principal Investigator:
- Roman Sztajzel, MD
-
Lausanne, Switzerland
- Recruiting
- University Hospital of Lausanne, Department of Neurology
-
Contact:
- Patrik Michel, MD
- Phone Number: +41 21 314 11 85
- Email: patrik.michel@chuv.hospvd.ch
-
Principal Investigator:
- Patrik Michel, MD
-
Zurich, Switzerland, 8091
- Recruiting
- University Hospital of Zurich, Department of Neurology
-
Contact:
- Ralf W Baumgartner, MD
- Phone Number: +41 1 255 56 86
- Email: ralf.baumgartner@usz.ch
-
Contact:
- Dimitrios Georgiadis, MD
- Email: dimitrios.georgiadis@usz.ch
-
Principal Investigator:
- Ralf W Baumgartner, MD
-
Principal Investigator:
- Dimitrios Georgiadis, MD
-
Sub-Investigator:
- Hakan Sarikaya, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- acute ischemic stroke in the MCA territory according to clinical and cranial computed tomography (CT) or cranial MR imaging (MRI) findings
- patient undergoing iv thrombolysis with t-PA within 3 hours after stroke onset
- Occlusion of sphenoidal (M1) or insular (M2) segment of the MCA at CT (CTA), MR (MRA) or catheter (CA) angiography
- appropriate temporal bony window without echocontrast agents for insonation with TCCS
- full functional independence prior to present stroke (mRS 0-1), use of a cane for walking due to comorbid condition is acceptable
- written informed consent, signed and dated by the subject (or subject's authorized representative, if allowed by local laws) and by the person obtaining the consent, indicating agreement to comply with all protocol-specific procedures
Exclusion Criteria:
- unconsciousness (more than 2 points on item 1a on NIHSS)
- history of intracranial hemorrhage, arteriovenous malformation or aneurysm
- severe cranio-cerebral trauma within the last 3 months
- symptoms of subarachnoidal hemorrhage
- time of symptom onset unclear
- large surgical intervention or trauma within the last 10 days
- expected survival below 90 days after iv t-PA treatment
- severe hepatic disease, esophageal varices, acute pancreatitis
- septic embolism, endocarditis, pericarditis after myocardial infarction
- pregnancy or childbirth within the last 30 days or nursing mothers
- history of hemorrhagic diathesis or coagulopathy
- untreatable increase of arterial blood pressure (>185mmHg systolic, >110mmHg diastolic)
- intracranial hemorrhage, arteriovenous malformations or aneurysm at brain imaging
- thrombocytes <100'000 per microliter
- international normalized ratio (INR)>1.7 or partial thromboplastin time (PTT) prolongated
- serum glucose <2.7mmol/l or >22.2mmol/l
- severe renal insufficiency or other contraindications against CT-contrast agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Symptomatic intracranial hemorrhage (safety)
|
Functional outcome (efficacy)
|
Secondary Outcome Measures
Outcome Measure |
---|
Asymptomatic intracranial hemorrhage 24-48 hours after t-PA infusion
|
Early clinical recovery by 10 or more NIHSS points or dramatic recovery (total NIHSS 3 or less)at 24-48 hours after t-PA infusion
|
Mean mRS score at 90 days after t-PA infusion
|
Death occurring during study period
|
Recanalization at 24-48 hours after t-PA infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Ralf W Baumgartner, MD, University Hospital of Zurich, Department of Neurology, Zurich, Switzerland
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Study Completion (Anticipated)
June 1, 2009
Study Registration Dates
First Submitted
June 13, 2006
First Submitted That Met QC Criteria
June 13, 2006
First Posted (Estimate)
June 14, 2006
Study Record Updates
Last Update Posted (Estimate)
April 27, 2007
Last Update Submitted That Met QC Criteria
April 25, 2007
Last Verified
April 1, 2007
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Embolism and Thrombosis
- Brain Ischemia
- Infarction
- Stroke
- Brain Infarction
- Cerebral Arterial Diseases
- Intracranial Arterial Diseases
- Intracranial Embolism and Thrombosis
- Thromboembolism
- Cerebral Infarction
- Embolism
- Thrombosis
- Infarction, Middle Cerebral Artery
- Intracranial Embolism
Other Study ID Numbers
- E-031/2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombosis
-
Università degli Studi dell'InsubriaOttawa Hospital Research InstituteUnknownPortal Vein Thrombosis | Mesenteric Vein Thrombosis | Splenic Vein ThrombosisCanada, Italy
-
University of MaltaUniversità degli Studi dell'InsubriaRecruitingCerebral Vein Thrombosis | Renal Vein Thrombosis | Retinal Vein Thrombosis | Splanchnic Vein Thrombosis | Ovarian Vein ThrombosisThailand, Spain, United States, Italy, Slovenia, France, Israel, Canada, Malta, Netherlands
-
Capital Medical UniversityBeijing Municipal Science & Technology CommissionNot yet recruitingCerebral Venous Sinus Thrombosis | Deep Cerebral Vein Thrombosis | Cortical Vein Thrombosis
-
University of AlbertaSanofi; Edmonton Civic Employees Research FundTerminatedPortal Vein Thrombosis | Splenic Vein ThrombosisCanada
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Malignant Neoplasm | Portal Vein Thrombosis | Metastatic Malignant Neoplasm | Cerebral Vein Thrombosis | Renal Vein Thrombosis | Gonadal Thrombosis | Hepatic Thrombosis | Mesenteric Thrombosis | Splenic ThrombosisUnited States
-
Assiut UniversityNot yet recruitingPortal Vein Thrombosis
-
Azienda Ospedaliera Universitaria PoliclinicoCompletedDeep Vein ThrombosisItaly
-
University of OklahomaPfizerCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSplanchnic Vein ThrombosisItaly
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
Clinical Trials on transcranial ultrasound in patients treated with iv t-PA
-
University of Colorado, DenverCompletedCovid19United States
-
Kansas City Heart Rhythm Research FoundationUnknownAtrial Fibrillation | Cardiac ArrhythmiaUnited States
-
The Greater Poland Cancer CentreActive, not recruiting
-
Maxima Medical CenterRadboud University Medical Center; Catharina Ziekenhuis Eindhoven; The Netherlands... and other collaboratorsRecruitingOvarian Cancer | Ovarian TumorNetherlands
-
Military Institute od Medicine National Research...CompletedEarly Release of Chromogranin A (CgA)
-
Assiut UniversityUnknownChronic Myeloid Leukemia Patients
-
Sunnybrook Health Sciences CentreMultiple Sclerosis Society of CanadaUnknown
-
Rennes University HospitalCompleted
-
Providence Health & ServicesGenentech, Inc.; Institute for Systems BiologyActive, not recruitingMultiple SclerosisUnited States
-
Derince Training and Research HospitalMehmet YilmazRecruitingPerfusion İndexTurkey